Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Drug company (FDA labeler)

Mayne Pharma Commercial LLC

NDC labeler codes: 51862, 68308

What is a labeler?

The company whose name is on the package and in the FDA’s National Drug Code (NDC) Directory. It may make the medicine itself or sell medicine made by another company. The first part of every NDC code identifies the labeler.

Official FDA data only

Products, approvals and recalls come from the FDA (NDC Directory, Drugs@FDA, enforcement reports). Recalls are linked to this company by the NDC labeler code on the recalled product.

Questions about your medicine: ask your doctor or pharmacist. In an emergency, call 911.

At a glance

11Products (NDC)

Prescription medicines

FDA applications for these products

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
  • ANDA: Abbreviated New Drug Application: how a generic version is approved.
ApprovedApplicationMedicineSponsor
April 22, 2022NDA214510 Benzoyl peroxide
EPSOLAY
Mayne Pharma
February 10, 2022ANDA214722 Dapsone
DAPSONE
Torrent
July 26, 2021NDA214902 Benzoyl peroxide and tretinoin
TWYNEO
Mayne Pharma
October 13, 2020ANDA211297 Tavaborole
TAVABOROLE
Encube
July 21, 2020ANDA211849 Chlorzoxazone
CHLORZOXAZONE
DR Reddys Labs SA
December 11, 2018NDA208901 Itraconazole
TOLSURA
Mayne Pharma
April 21, 2010ANDA091189 Methamphetamine hydrochloride
METHAMPHETAMINE HYDROCHLORIDE
DR Reddys Labs SA
June 19, 2007NDA021753 Adapalene
DIFFERIN
Galderma Labs LP
May 6, 2005NDA050795 Doxycycline
DORYX, DORYX MPC
Mayne Pharma
February 20, 2003ANDA075797 Tamoxifen citrate
TAMOXIFEN CITRATE
DR Reddys Labs SA

The sponsor is the company that holds the FDA application; it can differ from the labeler.

Recall timeline

2022

  1. June 9, 2022 · Class II · Terminated · D-1152-2022 · Clonidine

    Defective Delivery System: Out of specification for release liner removal force results at the 3-month CRT stability timepoint.

    Clonidine Transdermal System, USP 0.3 mg/day, 4 Patches (NDC 51862-455-01) per Carton (51862-455-04), Rx only, Manufactured for: Mayne Pharma Greenville, NC 27834

2018

  1. March 21, 2018 · Class III · Terminated · D-0616-2018 · Tazarotene

    Superpotent Drug: High out of specification results for tazarotene assay at the 9-month stability time point.

    Fabior (tazarotene) Foam, 0.1%, 100 grams can, Rx only, Distributed by: Mayne Pharma, Greenville, NC 27834; NDC 51862-295-10.

What do the recall classes mean?

Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).

Sources

  1. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  2. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  3. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026

FDA Enforcement Report search → · Report an error →